[{"address1": "2-1-1 Nihonbashi-Muromachi", "city": "Chuo", "zip": "103-8324", "country": "Japan", "phone": "81 3 3281 6611", "fax": "81 3 3281 6607", "website": "https://www.chugai-pharm.co.jp", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.", "fullTimeEmployees": 7604, "companyOfficers": [{"maxAge": 1, "name": "Dr. Osamu  Okuda", "age": 60, "title": "President, CEO & Chairman", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 1687392, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Iwaaki  Taniguchi", "age": 56, "title": "Executive VP, Head of Finance Supervisory Division, CFO & Director", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Toshiya  Sasai", "title": "Executive of Investor Relations Group & Corporate Communications Department", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Masayoshi  Higuchi", "title": "VP and Head of Quality, Regulatory Compliance Unit, Business Strategy & Compliance Dept.", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Junichi  Takano", "title": "Head of Marketing & Sales Division", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Shinji  Hidaka", "title": "Executive Vice President", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Junichi  Ebihara", "title": "Executive Vice President", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yoshiaki  Ohashi", "age": 63, "title": "Senior VP & Full-time Audit Supervisory Board Member", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tetsuya  Yamaguchi", "title": "Executive VP & Head of PHC Solution Unit", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yoshiyuki  Yano", "title": "Executive Vice President", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 1, "boardRisk": 7, "compensationRisk": 1, "shareHolderRightsRisk": 2, "overallRisk": 5, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://www.chugai-pharm.co.jp/hc/ss/english/ir/index.html", "maxAge": 86400, "priceHint": 2, "previousClose": 30.36, "open": 30.36, "dayLow": 30.36, "dayHigh": 30.36, "regularMarketPreviousClose": 30.36, "regularMarketOpen": 30.36, "regularMarketDayLow": 30.36, "regularMarketDayHigh": 30.36, "dividendRate": 0.56, "dividendYield": 0.0124, "exDividendDate": 1735257600, "payoutRatio": 0.3754, "beta": 0.534, "trailingPE": 31.194443, "forwardPE": 28.794872, "volume": 100, "regularMarketVolume": 100, "averageVolume": 14012, "averageVolume10days": 88640, "averageDailyVolume10Day": 88640, "bid": 44.07, "ask": 48.98, "bidSize": 21500, "askSize": 46000, "marketCap": 76962324480, "fiftyTwoWeekLow": 29.75, "fiftyTwoWeekHigh": 52.22, "priceToSalesTrailing12Months": 0.07096114, "fiftyDayAverage": 47.48468, "twoHundredDayAverage": 38.42951, "trailingAnnualDividendRate": 81.0, "trailingAnnualDividendYield": 2.6679842, "currency": "USD", "enterpriseValue": -741743460352, "profitMargins": 0.32736, "floatShares": 639462865, "sharesOutstanding": 1645469952, "heldPercentInsiders": 0.59911996, "heldPercentInstitutions": 0.18398, "impliedSharesOutstanding": 1713319936, "bookValue": 1064.553, "priceToBook": 0.042196114, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": 0.345, "netIncomeToCommon": 355040985088, "trailingEps": 1.44, "forwardEps": 1.56, "pegRatio": 648.16, "lastSplitFactor": "3:1", "lastSplitDate": 1593388800, "enterpriseToRevenue": -0.684, "enterpriseToEbitda": -1.432, "52WeekChange": 0.4923588, "SandP52WeekChange": 0.39070773, "lastDividendValue": 0.255, "lastDividendDate": 1719446400, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "CHGCF", "underlyingSymbol": "CHGCF", "shortName": "CHUGAI PHARMACEUTICAL CO", "longName": "Chugai Pharmaceutical Co., Ltd.", "firstTradeDateEpochUtc": 1344000600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "0db76804-27c0-3882-bffb-8f19fb3eeeda", "messageBoardId": "finmb_685347", "gmtOffSetMilliseconds": -14400000, "currentPrice": 44.92, "recommendationKey": "none", "totalCash": 815657975808, "totalCashPerShare": 495.699, "ebitda": 518099009536, "quickRatio": 4.018, "currentRatio": 5.087, "totalRevenue": 1084570009600, "revenuePerShare": 659.179, "returnOnAssets": 0.15625, "returnOnEquity": 0.21747999, "freeCashflow": 213306376192, "operatingCashflow": 327067992064, "earningsGrowth": 0.344, "revenueGrowth": 0.181, "grossMargins": 0.69461995, "ebitdaMargins": 0.4777, "operatingMargins": 0.50116, "financialCurrency": "JPY", "trailingPegRatio": 6.0845, "__fetch_time": "2024-10-21"}]